Sign up for Table of Contents Alerts.

Email this page

Print this page

Extra Views

Dissecting resistance to endocrine therapy in breast cancer

Christopher J. Lord, Elizabeth Iorns and Alan Ashworth

Purchase article for $19

Subscribe to this journal for $129/year

Drugs that target the reliance of tumour cells upon estrogen signalling have revolutionised the treatment of breast cancer. Despite this, resistance to these endocrine therapies limits their utility. While the study of individual genes has contributed greatly to understanding drug resistance, relatively unbiased screening approaches may also be illuminating. The results of a high-throughput RNA interference screen identifying novel determinants of tamoxifen resistance support this conjecture and demonstrate that such approaches can identify clinically relevant genes, such as CDK10.

Authors

Christopher J. Lord

The Institute of Cancer Research; London, UK

Elizabeth Iorns

The Institute of Cancer Research; London, UK

Alan Ashworth

The Institute of Cancer Research; London, UK

Purchase article for $19

Subscribe to this journal for $129/year